Takeda Pharmaceutical Company Limited

BOVESPA:TAKP34 Stock Report

Market Cap: R$260.2b

Takeda Pharmaceutical Management

Management criteria checks 2/4

Takeda Pharmaceutical's CEO is Christophe Weber, appointed in Jun 2014, has a tenure of 10.5 years. total yearly compensation is ¥2.08B, comprised of 15.2% salary and 84.8% bonuses, including company stock and options. directly owns 0.05% of the company’s shares, worth R$129.03M. The average tenure of the management team and the board of directors is 7.2 years and 8.5 years respectively.

Key information

Christophe Weber

Chief executive officer

JP¥2.1b

Total compensation

CEO salary percentage15.2%
CEO tenure10.5yrs
CEO ownership0.05%
Management average tenure7.2yrs
Board average tenure8.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Christophe Weber's remuneration changed compared to Takeda Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

JP¥290b

Jun 30 2024n/an/a

JP¥150b

Mar 31 2024JP¥2bJP¥317m

JP¥144b

Dec 31 2023n/an/a

JP¥178b

Sep 30 2023n/an/a

JP¥192b

Jun 30 2023n/an/a

JP¥301b

Mar 31 2023JP¥2bJP¥295m

JP¥317b

Dec 31 2022n/an/a

JP¥275b

Sep 30 2022n/an/a

JP¥213b

Jun 30 2022n/an/a

JP¥197b

Mar 31 2022JP¥2bJP¥281m

JP¥230b

Dec 31 2021n/an/a

JP¥439b

Sep 30 2021n/an/a

JP¥473b

Jun 30 2021n/an/a

JP¥431b

Mar 31 2021JP¥2bJP¥267m

JP¥376b

Dec 31 2020n/an/a

JP¥181b

Sep 30 2020n/an/a

JP¥56b

Jun 30 2020n/an/a

JP¥120b

Mar 31 2020JP¥2bJP¥273m

JP¥44b

Dec 31 2019n/an/a

JP¥13b

Sep 30 2019n/an/a

JP¥83b

Jun 30 2019n/an/a

JP¥64b

Mar 31 2019JP¥2bJP¥269m

JP¥135b

Dec 31 2018n/an/a

JP¥110b

Sep 30 2018n/an/a

JP¥141b

Jun 30 2018n/an/a

JP¥120b

Mar 31 2018JP¥1bJP¥254m

JP¥187b

Compensation vs Market: Christophe's total compensation ($USD13.19M) is above average for companies of similar size in the BR market ($USD5.71M).

Compensation vs Earnings: Christophe's compensation has increased by more than 20% in the past year.

CEO

Christophe Weber (58 yo)

10.5yrs

Tenure

JP¥2,083,000,000

Compensation

Mr. Christophe Weber has been the President and Chief Executive Officer of Takeda Pharmaceutical Company Limited since June 27, 2014 and April 2015 respectively and served as its Chief Operating Officer fr...

Leadership Team

NamePositionTenureCompensationOwnership
Christophe Weber
President10.5yrsJP¥2.08b0.050%
R$ 129.0m
Seigo Izumo
Chair of Management Boardno datano datano data
Milano Furuta
CFO & Directorless than a yearno data0.00083%
R$ 2.2m
Haruhiko Hirate
Member of Management Boardno datano datano data
Salvatore Alesci
Member of Management Board and Head of R&D Global Science & Biomedical Policyno datano datano data
Norimasa Takeda
Chief Accounting Officer & Corporate Controllerno datano datano data
Iwaaki Taniguchi
Senior Vice President of Corporate Finance & Controlling Department11.8yrsno datano data
Gabriele Ricci
Chief Data & Technology Officer2.8yrsno datano data
Christopher David O'Reilly
Global Head of Investor Relations & Global Finance4.3yrsno datano data
Yoshihiro Nakagawa
Global General Counsel10.2yrsno datano data
Mwana Lugogo
Chief Ethics & Compliance Officer10.2yrsno datano data
Lauren Duprey
Chief Human Resources Officer3.9yrsno datano data

7.2yrs

Average Tenure

51.5yo

Average Age

Experienced Management: TAKP34's management team is seasoned and experienced (7.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christophe Weber
President10.5yrsJP¥2.08b0.050%
R$ 129.0m
Milano Furuta
CFO & Directorno datano data0.00083%
R$ 2.2m
Andrew S. Plump
President of Research & Development and Representative Director9.5yrsJP¥972.00m0.0087%
R$ 22.7m
John M. Maraganore
Independent External Director2.5yrsJP¥32.00mno data
Steven S. Gillis
Independent External Director5.9yrsJP¥44.00m0.00026%
R$ 676.6k
Emiko Higashi
Independent External Director8.5yrsJP¥49.00m0.00016%
R$ 416.4k
Yoshiaki Fujimori
Independent External Director8.5yrsJP¥40.00m0.00079%
R$ 2.1m
Ian T. Clark
Independent External Director5.9yrsJP¥44.00m0.000070%
R$ 182.2k
Jean-Luc Butel
Independent External Director5.5yrsJP¥38.00mno data
Michel Orsinger
Independent External Director8.5yrsJP¥46.00mno data
Masami Iijima
Independent External Chair3.5yrsJP¥43.00m0.000020%
R$ 52.0k
Koji Hatsukawa
Independent External Director8.5yrsJP¥43.00m0.00063%
R$ 1.6m

8.5yrs

Average Tenure

66.5yo

Average Age

Experienced Board: TAKP34's board of directors are considered experienced (8.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 12:48
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Takeda Pharmaceutical Company Limited is covered by 38 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hazim BahariCFRA Equity Research